CA2909303C - Sustained release microspheres and method of producing the same - Google Patents

Sustained release microspheres and method of producing the same Download PDF

Info

Publication number
CA2909303C
CA2909303C CA2909303A CA2909303A CA2909303C CA 2909303 C CA2909303 C CA 2909303C CA 2909303 A CA2909303 A CA 2909303A CA 2909303 A CA2909303 A CA 2909303A CA 2909303 C CA2909303 C CA 2909303C
Authority
CA
Canada
Prior art keywords
dispersed phase
solvent
filtering
betamethasone
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2909303A
Other languages
English (en)
French (fr)
Other versions
CA2909303A1 (en
Inventor
Tracy RICHEY
Bagavathikanun Chithambara Thanoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oakwood Laboratories LLC
Original Assignee
Oakwood Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oakwood Laboratories LLC filed Critical Oakwood Laboratories LLC
Publication of CA2909303A1 publication Critical patent/CA2909303A1/en
Application granted granted Critical
Publication of CA2909303C publication Critical patent/CA2909303C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
CA2909303A 2013-03-15 2014-03-14 Sustained release microspheres and method of producing the same Active CA2909303C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790554P 2013-03-15 2013-03-15
US61/790,554 2013-03-15
PCT/US2014/028657 WO2014144309A1 (en) 2013-03-15 2014-03-14 Sustained release microspheres and method of producing the same

Publications (2)

Publication Number Publication Date
CA2909303A1 CA2909303A1 (en) 2014-09-18
CA2909303C true CA2909303C (en) 2021-10-19

Family

ID=51537672

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2909303A Active CA2909303C (en) 2013-03-15 2014-03-14 Sustained release microspheres and method of producing the same

Country Status (8)

Country Link
US (1) US9956177B2 (https=)
EP (1) EP2968184B1 (https=)
JP (2) JP2016515517A (https=)
CN (1) CN105705141B (https=)
CA (1) CA2909303C (https=)
ES (1) ES2697696T3 (https=)
MX (1) MX362187B (https=)
WO (1) WO2014144309A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9956177B2 (en) 2013-03-15 2018-05-01 Oakwood Laboratories LLC Sustained release microspheres and method of producing same
CN113766952B (zh) * 2019-03-29 2023-09-08 国立研究开发法人量子科学技术研究开发机构 放射性药品的制造方法及放射性药品
JP2023551508A (ja) * 2020-11-30 2023-12-08 エルジー・ケム・リミテッド カスパーゼ阻害剤を含有する注射用組成物及びその製造方法
US11992559B2 (en) 2021-02-24 2024-05-28 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
US20240148662A1 (en) * 2021-03-11 2024-05-09 Oakwood Laboratories, Llc Methods and systems for making polymer microspheres
CN116999412A (zh) * 2023-08-03 2023-11-07 四川迈可隆生物科技有限公司 一种含有倍他米松药物的缓释微球制剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
WO2002078673A1 (fr) * 2001-03-29 2002-10-10 Takeda Chemical Industries, Ltd. Procede de production d'un medicament sous forme de granules fins
JP2002356419A (ja) * 2001-03-29 2002-12-13 Takeda Chem Ind Ltd 微粒薬物の製造法
WO2005107714A2 (en) * 2004-05-05 2005-11-17 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
GB2459910B (en) 2008-04-21 2010-03-31 Otonomy Inc Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders
US20100086596A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for releasing an octreotide compound without an initial time lag
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
UA111162C2 (uk) * 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
US8708159B2 (en) * 2011-02-16 2014-04-29 Oakwood Laboratories, Llc Manufacture of microspheres using a hydrocyclone
US9956177B2 (en) 2013-03-15 2018-05-01 Oakwood Laboratories LLC Sustained release microspheres and method of producing same

Also Published As

Publication number Publication date
MX2015012231A (es) 2016-05-05
MX362187B (es) 2019-01-08
JP2016515517A (ja) 2016-05-30
EP2968184B1 (en) 2018-10-24
US20160030351A1 (en) 2016-02-04
ES2697696T3 (es) 2019-01-25
JP6808777B2 (ja) 2021-01-06
BR112015022524A2 (pt) 2017-08-22
JP2019112471A (ja) 2019-07-11
WO2014144309A1 (en) 2014-09-18
CN105705141A (zh) 2016-06-22
EP2968184A4 (en) 2016-09-07
CA2909303A1 (en) 2014-09-18
CN105705141B (zh) 2018-12-28
EP2968184A1 (en) 2016-01-20
US9956177B2 (en) 2018-05-01

Similar Documents

Publication Publication Date Title
JP6808777B2 (ja) 徐放性ミクロスフェア及びその製造方法
De Cicco et al. Prilling and supercritical drying: A successful duo to produce core-shell polysaccharide aerogel beads for wound healing
Cheng et al. Characterization and in vitro release of praziquantel from poly (ɛ-caprolactone) implants
KR101834940B1 (ko) 나노입자 제조방법
CA2904432A1 (en) High drug load buprenorphine microspheres and method of producing the same
KR102237737B1 (ko) 도네페질 함유 서방출성 plga 미립구의 제조방법
DE69715191T2 (de) Verfahren zur Herstellung von Mikropartikeln
KR20220112737A (ko) 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법
KR102223812B1 (ko) 난용성 약물 서방출용 미립구의 제조방법
WO2018172494A1 (de) Extrudierte depotform zur anhaltenden wirkstofffreisetzung
KR20210054660A (ko) 초기 방출 제어가 가능한 서방출성 미립구 및 이의 제조 방법
WO2023015851A1 (zh) 一种注射用曲安奈德微球植入剂及其制备方法
KR102427305B1 (ko) 국소 투여용 이중 봉입 생분해성 고분자 미립구의 제조방법 및 이를 포함하는 주사제
KR20200127964A (ko) 난용성 약물 서방출용 미립구의 제조방법
JP2016515517A5 (https=)
EP3675818B1 (en) Processing method for biopolymers using solvent combinations
KR101794032B1 (ko) 나노입자 제조방법
JP2023538901A (ja) ケタミンを含むマイクロスフェア製剤ならびにその製造及び使用方法
KR102700719B1 (ko) 덱사메타손 아세테이트를 포함하는 서방형 주사제제 및 그 제조방법
EP4031108B1 (de) Extrudierte depotform mit kontrollierter wirkstofffreisetzung
BR112015022524B1 (pt) Método de produção de uma formulação de microesferas de liberação sustentada e formulação de liberação sustentada
DE112006001606T5 (de) Nanopartikuläre und eine kontrollierte Freisetzung aufweisende Zusammensetzung, die Cefditoren umfassen
CN120960132A (zh) 一种莫匹罗星软膏的药物组合物及其制备方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190226

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250303

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250303